Table 2. Results of mapatumumab, an agonistic antibodies targeting TRAIL-R1 in clinical trials.
|
Mapatumumab (HGS-ETR1) | ||||||
|---|---|---|---|---|---|---|
| Phase | n | Cancer | Combination | Safety | Efficacy | Reference |
| I | 49 | Advanced cancers | — | Safe | No responses | 145 |
| I | 41 | Advanced cancers | — | Safe | No responses | 146 |
| I | 49 | Advanced cancers | Chemo | Safe | 12 Responses (12PR) | 147 |
| I | 27 | Advanced cancers | Chemo | Safe | 5 Responses (5PR) | 148 |
| I/II | 40 | Lymphoma | — | Safe | 3 Responses (2CR/1PR) | 149 |
| II | 38 | Colorectal | — | Safe | No responses | 150 |
| II | 32 | Lung | — | Safe | No responses | 151 |
| II (RCT) | 104 | Multiple myeloma | Bortezomib | Safe | No anticancer activitya | 121 |
| II (RCT) | 109 | Lung | Chemo | Safe | No anticancer activitya | 152 |
Abbreviations: chemo, chemotherapy; CR, complete response; n, number of patients enrolled; PR, partial response; RCT, randomized-controlled trial
a
Anticancer activity was considered when the addition of the TRA demonstrated statistically significant activity compared with the standard therapy